Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...

Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...

HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in ...

Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...

Astellas Pharma has announced that the National Institute for Health and Care Excellence has issued Final Draft Guidance recommending fezolinetant 45 mg once daily for treating moderate to severe ...

After years in this game, you realise (to paraphrase) that the more things stay the same, the more they constantly change. On this note, a wave of innovative medicines is set to reshape global ...

Aplagon has dosed the first patient in its phase 2a HEALING clinical trial evaluating APAC, a first‑in‑class treatment for thrombo‑inflammatory diseases, in people with peripheral arterial occlusive ...

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

The Healthcare Communications Association (HCA) interviews senior leaders from across pharma to explore how healthcare communications must evolve in the face of growing complexity, accelerating ...